GSK_Annual_Report_2021

Nucala Innovative biologic for Severe Eosinophilic Asthma Launched in 2019, Nucala provides strong and lasting protection against exacerbations and oral steroid dependency in Severe Eosinophilic Asthma (SEA). It reduces exacerbations in SEA patients by 53% to 73%.  In FY 2020, GSK launched the “Nucala Home Administration Programme” for eligible patients to enable them continuity in treatment, considering the restrictions and challenges faced by patients owing to the pandemic  A Severe Asthma Clinic programme was launched to support HCPs in early diagnosis and phenotyping of severe asthma patients Global developments Our approach to R&D focusses on the science of immune system, genetics, and advanced technologies. Our R&D pipeline currently comprises 59 vaccines and medicines, predominantly in the areas of infectious diseases, oncology and immune-mediated diseases. We have identified over 20 potential product approvals which could take place by 2026. Focus on COVID-19 collaborations Since the pandemic began, our parent entity GSK plc. has been seeking ways to harness our scientific expertise and technology to make a real difference in the society. As a result, we are working with several partners to develop potential COVID-19 vaccines and treatments as quickly and safely as possible. Some of its key highlights include:  Collaboration with Vir Biotechnology to develop new dual action monoclonal antibodies, which could be used as therapeutic or preventive options for COVID-19. We have received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (USFDA) for the same monoclonal antibody for treatment of mild-to-moderate COVID-19 in high risk adults and pediatric patients  Collaboration with Sanofi, combining their vaccine candidate with our adjuvant technology to develop an adjuvanted COVID-19 vaccine candidate. A Phase 3 clinical trial has been initiated  Collaboration with Medicago to develop a COVID-19 vaccine by combining their plant-derived vaccine candidate with our adjuvant technology. This vaccine candidate entered Phase 3 clinical trials in March 2021, with positive interim Phase 2 clinical trial data published in May 2021  Collaboration with CureVac to jointly develop next generation mRNA vaccines for COVID-19 with the potential to address multiple emerging variants. In addition, we aim to support manufacturing of 100 million doses of CureVac’s first-generation COVID-19 vaccine candidate in 2021 10 Company Overview GlaxoSmithKline Pharmaceuticals Limited